{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:41:00Z","timestamp":1790692860842,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2004,3,18]],"date-time":"2004-03-18T00:00:00Z","timestamp":1079568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Lung carcinomas show frequent inactivation of the p53 tumor suppressor, which regulates an apoptotic pathway. The objective of the current study was to assess how the p53 apoptotic pathway is altered in nonsmall cell lung carcinoma (NSCLC), especially in tumors without p53 alterations.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>p53, its upstream regulators (p14<jats:sup>ARF<\/jats:sup> and HDM2), and downstream effectors of the apoptotic pathway (BAX and BCL2) were studied in 118 NSCLC specimens. p53 was analyzed by single\u2010stranded conformation polymorphism analysis covering exons 2\u201311 and by immunohistochemistry (IHC). p14<jats:sup>ARF<\/jats:sup> was analyzed by methylation\u2010specific polymerase chain reaction and IHC. HDM2 was analyzed using Southern blot analysis and IHC. BAX and BCL2 were analyzed by IHC. Two other upstream regulators that regulate the stability of HDM2, PTEN and HAUSP, also were studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 118 NSCLC specimens that were analyzed, p53 alterations were detected in 74 tumors (63%), p14<jats:sup>ARF<\/jats:sup> inactivation was detected in 53 tumors (45%), and overexpression of HDM2 was found in 31 tumors (26%), including 6 tumors with gene amplification. Although p53 inactivation and HDM2 overexpression were detected simultaneously, <jats:italic>HDM2<\/jats:italic> gene amplification was observed only in tumor specimens without p53 mutations. IHC revealed PTEN down\u2010regulation in 22 of 88 tumors (25%). <jats:italic>HAUSP<\/jats:italic> Northern blot analysis demonstrated several\u2010fold differences in gene expression that did not correlate with p53 alterations. Of 118 NSCLC specimens, expression of BAX and BCL2 expression were detected in 46 tumors (39%) and 17 tumors (14%), respectively. Finally, ASPP1 and ASPP2, molecules involved in mediating the transcription function of p53, were not found to be aberrantly expressed when tested by Northern blot analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Overall, two or more p53 pathway components were found to be frequently altered in patients with NSCLC. Greater than 90% of the alterations were due to abnormalities of p53, p14<jats:sup>ARF<\/jats:sup>, or HDM2. Therefore, the inactivation of one or more components of the p53 pathway appears to be a prerequisite for the development of most NSCLCs. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20164","type":"journal-article","created":{"date-parts":[[2004,3,30]],"date-time":"2004-03-30T19:01:29Z","timestamp":1080673289000},"page":"1673-1682","source":"Crossref","is-referenced-by-count":58,"title":["p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma"],"prefix":"10.1002","volume":"100","author":[{"given":"Shoichi","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwun M.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Shimokata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,3,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-419X(98)00010-9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.205"},{"key":"e_1_2_6_5_2","first-page":"625","article-title":"Meta\u2010analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers","volume":"8","author":"Tammemagi MC","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"e_1_2_6_6_2","first-page":"4055","article-title":"Prognostic significance of p53 alterations in patients with non\u2010small cell lung cancer: a meta\u2010analysis","volume":"6","author":"Mitsudomi T","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(99)00038-6"},{"key":"e_1_2_6_8_2","first-page":"3926","article-title":"The human p19ARF protein encoded by the beta transcript of the p16INK4a is frequently lost in small cell lung cancer","volume":"58","author":"Gazzeri S","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202501"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.221"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.60"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205359"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(02)02166-7"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202070"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201956"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)01761-5"},{"key":"e_1_2_6_17_2","first-page":"1941","article-title":"Apoptosis\u2010related factors p53, Bcl2, and Bax in neuroendocrine lung tumors","volume":"149","author":"Brambilla E","year":"1996","journal-title":"Am J Pathol."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90391-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690152"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature737"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00367-7"},{"key":"e_1_2_6_22_2","volume-title":"TNM classification of malignant tumours","author":"Sobin LH","year":"1997"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60049-4"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204557"},{"key":"e_1_2_6_25_2","first-page":"2416","article-title":"Preferential expression of c\u2010kit protooncogene transcripts in small cell lung cancer","volume":"51","author":"Sekido Y","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(02)00536-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2456"},{"key":"e_1_2_6_28_2","first-page":"4244s","article-title":"Use of a monoclonal anti\u2010estrogen receptor antibody in the immunohistochemical evaluation of human tumors","volume":"46","author":"McCarty KS","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_6_29_2","first-page":"129","article-title":"Hypermethylation\u2010associated inactivation of p14\n                  \n                     ARF\n                   is independent of p16\n                  \n                     INK4a\n                   methylation and p53 mutational status","volume":"60","author":"Esteller M","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205581"},{"key":"e_1_2_6_31_2","first-page":"1971","article-title":"DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies","volume":"13","author":"Casey G","year":"1996","journal-title":"Oncogene."},{"key":"e_1_2_6_32_2","first-page":"927","article-title":"Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes","volume":"15","author":"Fujita T","year":"1999","journal-title":"Int J Oncol."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7382"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(02)00645-3"},{"key":"e_1_2_6_35_2","first-page":"544","article-title":"Immunohistochemical and molecular evaluation of the mdm\u20102 gene product in bronchogenic carcinoma","volume":"9","author":"Gorgoulis VG","year":"1996","journal-title":"Mod Pathol."},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.12.6937"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.181181198"},{"key":"e_1_2_6_38_2","first-page":"1178","article-title":"Lack of PTEN expression in non\u2010small cell lung cancer could be related to promoter methylation","volume":"8","author":"Soria JC","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_39_2","first-page":"3986","article-title":"Akt\/protein kinase B is constitutively active in non\u2010small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation","volume":"61","author":"Brognard J","year":"2001","journal-title":"Cancer Res."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20164","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:59:49Z","timestamp":1760266789000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,18]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,4,15]]}},"alternative-id":["10.1002\/cncr.20164"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20164","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,18]]}}}